Choose Your Country or Region

Pancreatic Cancer

Modeling Agent

Drugs Approved

Erlotinib (CP-358774) Hydrochloride

Gemcitabine Hydrochloride

Irinotecan Hydrochloride

Sunitinib (SU11248) Malate

Chemotherapy Regimens

FOLFIRINOX: Calcium Folinate; 5-Fluorouracil; Irinotecan Hydrochloride; Oxaliplatin

GEMCITABINE-CISPLATIN: Gemcitabine Hydrochloride; Cisplatin

GEMCITABINE-OXALIPLATIN: Gemcitabine Hydrochloride; Oxaliplatin

OFF: Oxaliplatin; 5-Fluorouracil; Calcium Folinate

GN: Gemcitabine; Nab-Paclitaxel

NALIRIFOX: Irinotecan; 5-Fluorouracil; Folinic acid; Oxaliplatin

S-1: Tegafur; Gimeracil; Potassium oxonate

mFOLFOX6: Folinic acid; 5-Fluorouracil; Oxaliplatin

ESMO Guidelines Recommendations ^[1]

First-Line Treatment: 5-Fluorouracil; Irinotecan Hydrochloride; Oxaliplatin; Nab-Paclitaxel; Folinic acid

Second-Line Treatment: 5-Fluorouracil; Gimeracil; Larotrectinib; Folinic acid; Calcium Folinate; Potassium oxonate; Oxaliplatin; Entrectinib

ICIs

PD-1: Pembrolizumab; Dostarlimab; Cemiplimab; Camrelizumab; Sintilimab; Nivolumab; Serplulimab; Balstilimab

PD-L1: Atezolizumab; Durvalumab; Avelumab; Adebrelimab; Sugemalimab

CALT-4: Nurulimab; Zalifrelimab; Quavonlimab; Ipilimumab; Tremelimumab

Anti-Angiogenesis

VEGF: Bevacizumab; RAD001; Axitinib; Sorafenib

EGFR: Panitumumab; Nimotuzumab; Demupitamab

PDGFR: Crenolanib; Ripretinib

c-kit: Masitinib

TKIs: Sunitinib; Sorafenib; Pazopanib

Targeted Therapy (A) ^[2]

CLDN18.2: Zolbetuximab

MSLN: Anetumab; Anetumab-MMAE

DNA: Lurbinectedin; Oxaliplatin; Streptozotocin; Evofosfamide

KRAS G12D: MRTX1133; KRpep-2d

Tubulin: Nab-Paclitaxel; Paclitaxel; Docetaxel

MUC1: Clivatuzumab; Cantuzumab; Gatipotuzumab; Clivatuzumab-MMAE

TOP1: Irinotecan Hydrochloride; Rubitecan

TYMS: Leucovorin (Folinic acid) Calcium Pentahydrate; Gimeracil; Capecitabine; Tegafur

Targeted Therapy (B) ^[2]

EGFR: Panitumumab; Nimotuzumab; Demupitamab

CD40: Giloralimab; Sotigalimab; Selicrelumab

FAK: Defactinib; GSK2256098; Narmafotinib; PF-562271; VS-4718

KRAS G12C: Adagrasib; LY3537982; ARS-853; K-Ras(G12C) inhibitor 12

STAT3: Napabucasin

CD73: Mupadolimab; Oleclumab; Uliledlimab; AB680; LY-3475070

CEACAM5: Tusamitamab; Labetuzumab; Cergutuzumab; Tusamitamab ravtansine; Labetuzumab govitecan

CSCs Marker ^[3]

CD44+CD24+ESA+: Curcumin

CD133: Metformin

CD44: Metformin; Angstrom6

EPCAM: Metformin

ALDH1: Metformin; Triptolide; Sulforaphane; Tetraethylthiuram disulfide; NCT-501

DCLK1: Licofelone; DCLK1-IN-1

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Tyrosine Kinase Inhibitor Library

Angiogenesis Related compound Library

MAPK Inhibitor Library

PI3K/Akt Inhibitor Library

References

https://pubmed.ncbi.nlm.nih.gov/37678671/
https://synapse.zhihuiya.com/drug-list?query_id=28ac8d45-f682-48d8-afb0-48c4be91680c
https://pubmed.ncbi.nlm.nih.gov/28137215/